Tests DS-3939a alone or with other drugs in adults with solid tumors
Tests DS-3939a, alone or with other cancer drugs, in adults with solid tumors.
Plain-language title generated from the registry record
Registry title: A Study of DS-3939a in Participants With Solid Tumors
Key facts
- Where
- Marseille, Montpellier, Paris, Rennes, Saint-Herblain, Suresnes, Vandœuvre-lès-Nancy, and Villejuif, FranceSee the 8 sites
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Which best describes your lung cancer?
- Has the cancer spread to other parts of the body, or is it too advanced to be removed by surgery?
- Has your cancer spread to the brain?
Source: NCT07739966, who can take part
Where in France
- APHM - Hopital NordMarseille, FranceNot yet recruiting
- Centre Hospitalier Universitaire de Montpellier (Chu Montpellier) - Hopital LapeyronieMontpellier, FranceNot yet recruiting
- Hospitalier Paris Saint-JosephParis, FranceNot yet recruiting
- Centre Hospitalier Universitaire (Chu) de Rennes - Hopital de PontchaillouRennes, FranceNot yet recruiting
- Institut de Cancerologie de l´Ouest (ICO) - Saint HerblainSaint-Herblain, FranceNot yet recruiting
- Hopital FochSuresnes, FranceNot yet recruiting
- Unicancer-Institut de Cancerologie de Lorraine (Icl)Vandœuvre-lès-Nancy, FranceNot yet recruiting
- Institut Gustave RoussyVillejuif, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Daiichi Sankyo
- Trial code
- NCT07739966EU 2026-525218-75-00
- Record updated
- 10 November 2026
- Original description
The primary purpose of the study is to evaluate the safety, tolerability, and efficacy of DS-3939a in combination with other anticancer agents or as a monotherapy in participants with solid tumors.Read full original descriptionShow less
A Phase 1b/2, Multicenter, 2-part, Open-label Trial to Evaluate DS-3939a in Participants With Solid Tumors
The primary purpose of the study is to evaluate the safety, tolerability, and efficacy of DS-3939a in combination with other anticancer agents or as a monotherapy in participants with solid tumors.
Inclusion: Sign and date the Main Trial informed consent form (ICF), prior to the start of any trial-specific procedures; Adults greater than or equal to (≥)18 years of age at the time the Main Trial ICF is signed (follow local regulatory requirements if the legal age of consent for trial participation is >18 years old); Histologically documented Stage IIIB, IIIC disease who is not candidate for surgical resection or definitive chemoradiation, or Stage IV NSQ NSCLC; Has a left ventricular ejection fraction (LVEF) ≥50 percent (%) by either an echocardiogram (ECHO) or multigated acquisition scan (MUGA) within 28 days of the first trial intervention; Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 assessed no more than 14 days prior to initiation of trial interventions; Has adequate organ function; Participants must have measurable disease by investigator assessment according to RECIST v1.1; Additional Inclusion Criteria for Substudy 1:; Participants must not have received prior systemic therapy for locally advanced unresectable or metastatic NSCLC; Additional Inclusion Criteria for Substudy 2:; Participants with AGA (excluding EGFR mutation): Participants have been previously treated with targeted therapy for the AGA and platinum-based chemotherapy for the advanced disease setting; Participants without AGA: Participants have been previously treated with platinum-based chemotherapy and anti-programmed death-1 (anti-PD-1)/programmed death-ligand 1 (PD-L1) antibody; Part 2 only: Participants must have received only 1 or 2 prior lines of anticancer therapy for the advanced disease setting.
Exclusion: Prior systemic anticancer therapy targeting MUC1 or TA-MUC1; Prior systemic anticancer therapy with topoisomerase 1 inhibitor or topoisomerase 1 inhibitor-based antibody-drug conjugate (ADCs) (e.g., datopotamab deruxtexan and Sacituzumab govitecan); Has multiple primary malignancies; Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use, or current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at screening; Has active or uncontrolled human immunodeficiency virus (HIV) infection; Has active or uncontrolled hepatitis B virus (HBV)/hepatitis C virus (HCV) infection; Has spinal cord compression or clinically active central nervous system (CNS) metastases; Any of the following within the past 6 months: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event; Current participation in other therapeutic investigational procedures, except for participation in long term survival follow-up (LTSFU) without any investigational treatment.